AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02219581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard multimodal pain management regimen
Description: The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain
Study NCT02219581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
Study NCT02738255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Varnum mouthpiece
Description: An adhesive mouthpiece with a central opening applied during sleep
Study NCT02300012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeons knowledge of pre-operative PBIs
Description: Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
Study NCT01105806 — intervention group
Intervention type: BEHAVIORAL
Intervention: (CPR) video and questionnaires
Description: Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
Study NCT03083561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641
Description: Administered orally.
Study NCT03083561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT01105806 — intervention group
Intervention type: BEHAVIORAL
Intervention: cardiopulmonary resuscitation (CPR) narrative script and questionnaires
Description: Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
Study NCT02063100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets
Description: Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
Study NCT02063100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50mg
Description: Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
Study NCT02063100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets and Losartan potassium 50mg
Description: Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
Study NCT02063100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets and Losartan potassium 100mg
Description: Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
Study NCT02063100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100mg
Description: Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
Study NCT02692690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulette r4x
Study NCT02926729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nonlinear microscopy imaging of excised surgical margins
Description: Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
Study NCT02994602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone + Testosterone Combination Gel
Description: The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
Study NCT02401373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-EBOV
Description: intramuscular injection
Study NCT02753205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
Study NCT02753205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: infusion of normal saline
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Six Day per week short daily hemodialysis
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Six nights per week nocturnal hemodialysis
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Every other day short daily hemodialysis
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: Every other night hemodialysis
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: 5 days per week short daily hemodialysis
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More frequent hemodialysis
Description: 5 nights per week hemodialysis
Study NCT00575497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hemodialysis
Description: 3 days per week short daily hemodialysis
Study NCT02152228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EnteraBio's Oral Parathyroid Hormone (1-34)
Description: Oral administration
Study NCT02795208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver
Description: The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
Study NCT03942679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PRP
Description: Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
Study NCT03942679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
Study NCT02035332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation System
Description: Ablation of the endometrial lining of the uterus using the Aurora System
Study NCT01272960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-Placenta Mirena Insertion
Description: Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
Study NCT02926729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard lumpectomy without nonlinear microscopy imaging
Description: Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
Study NCT03290456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5mg/day extended of 12 additional months
Description: Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
Study NCT01272960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interval Insertion
Description: Insertion of Mirena 4-8 weeks post partum after vaginal delivery
Study NCT03463915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bladder instillation WITH triamcinolone acetonide
Description: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
Study NCT03463915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bladder instillation WITHOUT triamcinolone acetonide
Description: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
Study NCT04845464 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment (not diagnostic)
Description: Sleep quality and cognition will be assessed in young adults
Study NCT02225379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-Sense (non invasive sensor)
Description: Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
Study NCT04319601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: a new chemotherapy regimen
Study NCT00297115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg, once daily, oral administration in the morning
Study NCT00297115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT02276066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GFR by Iohexol
Description: Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.
Study NCT02276066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GFR by Iohexol
Description: Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.
Study NCT02276066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Collection
Description: Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.
Study NCT02276066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine Collection
Description: Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.
Study NCT02276066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
Study NCT02276066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
Study NCT02393521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shindo® vibration mattress
Description: vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
Study NCT02571322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperVibe Whole Body Vibration training device
Description: Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
Study NCT02571322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
Study NCT01313546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of quariceps muscle
Description: stimulation of quadriceps muscle through the stimulating catheter
Study NCT03185832 — intervention group
Intervention type: DEVICE
Intervention: CRT-D
Description: This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
Study NCT03185832 — intervention group
Intervention type: DEVICE
Intervention: ICD
Description: This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
Study NCT03185832 — intervention group
Intervention type: DEVICE
Intervention: PM / CRT-P
Description: This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
Study NCT03185832 — intervention group
Intervention type: OTHER
Intervention: Non-device
Description: Patient enrolled but not implanted with a Defibrillator or Pacemaker
Study NCT03133104 — intervention group
Intervention type: OTHER
Intervention: Antenatal corticosteroids
Description: Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
Study NCT00369681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT00369681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT03290456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5mg/day extended of 12 additionnal months.
Description: 1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
Study NCT02263391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in or Opt-out testing
Description: Study participants will be offered a health screening onsite.
Study NCT00369681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study NCT00369681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT00369681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study NCT03675451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89ZR-DF-IAB2M
Description: injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
Study NCT03675451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC
Description: Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
Study NCT03906305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept
Description: Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)
Study NCT03906305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept
Description: Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)
Study NCT01401413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: 8 mg nightly for 30 nights
Study NCT02263391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Study participants will be invited to participate in a focus group discussion.
Study NCT02586610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Days 1, 22 and 43
Study NCT02586610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
Study NCT02586610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
Study NCT02683278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral
Description: Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
Study NCT02683278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-acceptance
Description: Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
Study NCT02683278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
Study NCT00536627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine pCMVS2.S
Description: Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
Study NCT01665222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets
Study NCT01401413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control i pill nightly for 30 nights
Study NCT02964455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
Study NCT02964455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
Study NCT02964455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: continuous chest radiation at 64 Gy/32f
Study NCT04581148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test antibodies against SARS-CoV-2
Description: Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
Study NCT01665222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets